Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 8 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- GLUcose Transport and REnalPROtection in Chronic Kidney DiseaseCompletedNCT05998837Phase 2/3
- Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by CardiotomographyCompletedNCT05998525Phase 3
- Initiation of ARNi and SGLT2i in Patients With HFrEFCompletedNCT05989503Phase 4
- Dapagliflozin in Patients With Ulcerative ColitisCompletedNCT05986136Phase 2/3
- Empagliflozin in Treatment of Peripheral Diabetic NeuropathyCompletedNCT05977465Phase 1/2
- SGLT2 Inhibitors in Treating Patients With PCOSCompletedNCT05966792Not applicable
- Efficacy and Safety of Empagliflozin in GSD-Ib PatientsWithdrawnNCT05960617Phase 2
- Mechanistic Insights to Weight Loss Maintenance Through SGLT2 InhibitorsWithdrawnNCT05885074Phase 2
- A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.CompletedNCT05884866Phase 2
- Novel Therapeutics and Endothelial Dysfunction in T1DM PatientsCompletedNCT05857085Phase 4
- Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle DysfunctionCompletedNCT05849766Phase 3
- Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.Status unknownNCT05849220Not applicable
- This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.Status unknownNCT05823883Phase 1
- This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.CompletedNCT05823870Phase 1
- Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin TherapyCompletedNCT05797935Phase 4
- Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid CardiomyopathyCompletedNCT05795400Not applicable
- Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive DisordersCompletedNCT05792540Phase 2
- Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?Active, not recruitingNCT05788276Phase 4
- Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot StudyActive, not recruitingNCT05782972Phase 4
- Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection FractionStatus unknownNCT05778084Phase 4
- SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With ObesityCompletedNCT05764811Not applicable
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)CompletedNCT05757791Phase 2
- The Fontan Dapagliflozin Pilot StudyCompletedNCT05741658Phase 4
- To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose CombinationStatus unknownNCT05737771Phase 1
- SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal InsufficiencyTerminatedNCT05737186Phase 4
- Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease PatientsCompletedNCT05735197Phase 4
- Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452CompletedNCT05722262Phase 1
- Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney DiseaseActive, not recruitingNCT05719714Phase 1/2
- Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)Status unknownNCT05717257Phase 4
- Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease PatientsStatus unknownNCT05710367Phase 2
- SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis PatientsCompletedNCT05704088Phase 4
- Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 DiabetesActive, not recruitingNCT05696366Phase 1/2
- Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue AssessmentCompletedNCT05694923Not applicable
- Empagliflozin in ESKD - A Feasibility StudyActive, not recruitingNCT05687058Phase 1/2
- SGLT2 Inhibitor for Severe Tricuspid RegurgitationStatus unknownNCT05686616Not applicable
- Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.CompletedNCT05681273Phase 1
- Dapagliflozin With or Without Spironolactone for HFpEFCompletedNCT05676684Phase 2/3
- Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting ConditionCompletedNCT05673369Phase 1
- Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy VolunteersActive, not recruitingNCT05662865Phase 1
- Dapagliflozin Therapy In Cardiac SurgeryCompletedNCT05621551Phase 4
- Dapagliflozin Effect on Rheumatic Mitral StenosisStatus unknownNCT05618223Phase 3
- Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKDCompletedNCT05614115Phase 1
- Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial RemodelingStatus unknownNCT05606718Phase 4
- Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic SteatohepatitisStatus unknownNCT05605158Phase 3
- Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary SyndromeCompletedNCT05601336Phase 3
- Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 DiabetesStatus unknownNCT05591235Phase 3
- proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2Active, not recruitingNCT05590143Phase 4
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "Status unknownNCT05580510Phase 2/3
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated AlbuminuriaCompletedNCT05570305Phase 2
- Effects of Acute and Chronic Empagliflozin Heart FailureActive, not recruitingNCT05553938Phase 1
- Effect of Dapagliflozin on VT in Patients With Heart Failure.Status unknownNCT05550441Phase 4
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin TherapyStatus unknownNCT05545800Phase 3
- Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for EpilepsyStatus unknownNCT05512130Early Phase 1
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT05510115Phase 2
- Renal Mechanism of SGLT2 InhibitionActive, not recruitingNCT05507892Phase 2
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminActive, not recruitingNCT05505994Phase 3
- Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male AdultsStatus unknownNCT05500898Phase 1
- Empagliflozin in Pulmonary Arterial HypertensionCompletedNCT05493371Phase 2
- PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive CareTerminatedNCT05468203Phase 3
- Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and CCompletedNCT05465668Phase 1
- Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT05459701Phase 4
- Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 DiabetesCompletedNCT05457933Phase 4
- Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 DiabetesStatus unknownNCT05440591Phase 4
- Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney InjurySuspendedNCT05435235Phase 4
- Empagliflozin as a Novel Therapy in Refractory AscitesCompletedNCT05430243Phase 2/3
- A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One TabletCompletedNCT05429593Phase 1
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver DamageCompletedNCT05427682Phase 1
- Use of Empagliflozin to Treat PrediabetesCompletedNCT05426525Phase 4
- Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic PatientsCompletedNCT05424315Phase 2/3
- Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver DiseaseStatus unknownNCT05422092Not applicable
- Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection FractionStatus unknownNCT05420285Phase 2
- Impact of SGLT2 on Glucosuria in HNF1A-MODYCompletedNCT05417646Not applicable
- Pharmacokinetics and Safety Following Administration of DWP16001CompletedNCT05414591Phase 1
- A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.CompletedNCT05411965Phase 1
- Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)CompletedNCT05406505Phase 2/3
- A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult VolunteersCompletedNCT05403281Phase 1
- Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic PatientsTerminatedNCT05392959Phase 4
- Obesity Treatment to Improve DiabetesCompletedNCT05390307Not applicable
- Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on MetforminCompletedNCT05376969Phase 3
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.CompletedNCT05376930Phase 3
- A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal ImpairmentCompletedNCT05374343Phase 1
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKDActive, not recruitingNCT05374291Phase 3
- Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease ProgressionCompletedNCT05373680Phase 2/3
- Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney DiseaseStatus unknownNCT05373004Phase 2/3
- Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsStatus unknownNCT05369078Phase 1
- Canagliflozin and Myocardial FibrosisCompletedNCT05367063Phase 4
- Canagliflozin in Patients With Acute Decompansted Heart FailureCompletedNCT05364190Phase 3
- The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury SurvivorsActive, not recruitingNCT05360615Phase 1
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes MellitusCompletedNCT05359432Phase 4
- Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?CompletedNCT05359341Not applicable
- Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis PatientsCompletedNCT05343078Phase 4
- Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction PatientsCompletedNCT05335629Not applicable
- The Effect of Inflammation in Heart FailureWithdrawnNCT05330013Phase 2
- Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisCompletedNCT05327127Phase 2
- The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy AdultsStatus unknownNCT05321732Phase 1
- DAPAgliflozin for Renal Protection in Heart Transplant RecipientsActive, not recruitingNCT05321706Phase 3
- Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized TrialStatus unknownNCT05314725Phase 2
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesCompletedNCT05313529Not applicable
- Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus PatientsStatus unknownNCT05310916Phase 3
- Safety and Efficacy of Canagliflozin in Advanced CKDCompletedNCT05309785Phase 4